Company Participation in Conferences - Nektar Therapeutics will webcast its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, and the Stifel Virtual Immunology and Inflammation Forum from September 15-16, 2025 [1][4] - Presentations will be accessible via webcast links and on the Investor Events section of the Nektar website, with replays available for 30 days [2] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator currently in two Phase 2b clinical trials for atopic dermatitis and alopecia areata [3] - The pipeline includes a preclinical bivalent TNFR2 antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified CSF protein NKTR-422 [3] - Nektar is also evaluating NKTR-255, an investigational IL-15 receptor agonist, in several ongoing clinical trials aimed at enhancing the immune system's ability to combat cancer [3]

Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The company's lead product candidate is rezpegaldesleukin (REZPEG, or NKTR-358), a first-in-class regulatory T cell stimulator currently in two Phase 2b clinical trials for atopic dermatitis and alopecia areata [3] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer, in several ongoing clinical trials [3] Upcoming Financial Results - Nektar Therapeutics will announce its financial results for the second quarter on August 7, 2025, after the close of U.S. financial markets [1] - Howard Robin, President and CEO, will host a conference call to review the results starting at 5:00 p.m. Eastern Time [1] Access to Conference Call - The press release and live audio-only webcast of the conference call can be accessed through a link on Nektar's website [2] - The web broadcast will be available for replay until September 7, 2025 [2] - Participants can pre-register for the conference call to receive dial-in information and a PIN [2]

Group 1 - Nektar Therapeutics closed an underwritten public offering of $115 million, selling 4,893,618 shares at a price of $23.50 per share [1][2] - The offering included 638,298 shares sold due to the underwriters' full exercise of their option to purchase additional shares [1] - The gross proceeds from the offering are approximately $115 million before deducting underwriting discounts and commissions [1] Group 2 - Nektar plans to use the net proceeds for general corporate purposes, including research and development, clinical development, and manufacturing costs [2] - Jefferies and Piper Sandler acted as joint bookrunning managers, with BTIG, LLC and H.C. Wainwright & Co. also involved in the offering [2] Group 3 - The securities were offered under a shelf registration statement filed with the SEC on March 28, 2025, and declared effective on April 1, 2025 [3] - A final prospectus supplement related to the offering is available on the SEC's website [4] Group 4 - Nektar Therapeutics is focused on developing treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (REZPEG, or NKTR-358) [6] - The company is evaluating several drug candidates, including NKTR-255, an investigational IL-15 receptor agonist designed to enhance the immune system's ability to fight cancer [6]

Core Viewpoint - Nektar Therapeutics has announced a public offering of $100 million in common stock, pricing the shares at $23.50 each, with the offering expected to close on July 2, 2025 [1][2]. Group 1: Offering Details - Nektar is selling 4,255,320 shares in the offering, with gross proceeds anticipated to be approximately $100 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 638,298 shares at the public offering price [1]. - Jefferies and Piper Sandler are the joint bookrunning managers, with BTIG, LLC as the passive bookrunner and H.C. Wainwright & Co. as co-manager [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including research and development, clinical development, and manufacturing costs to support drug candidates [2]. Group 3: Company Overview - Nektar Therapeutics is focused on developing innovative treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (REZPEG, or NKTR-358) [6]. - The company is conducting two Phase 2b clinical trials for REZPEG, targeting atopic dermatitis and alopecia areata [6]. - Nektar's pipeline includes additional candidates such as NKTR-255, an investigational IL-15 receptor agonist, and other preclinical programs [6].

Core Viewpoint - Nektar Therapeutics has initiated an underwritten public offering of its common stock and pre-funded warrants, with a potential additional 15% of shares available for underwriters [1][2] Group 1: Offering Details - The offering includes common stock and pre-funded warrants, with all shares being offered by Nektar [1] - Nektar plans to use the net proceeds for general corporate purposes, including research, development, and manufacturing costs [2] - Jefferies and Piper Sandler are acting as joint bookrunning managers for the offering [2] Group 2: Regulatory Information - The offering is conducted under a shelf registration statement filed with the SEC on March 28, 2025, and declared effective on April 1, 2025 [3] - A preliminary prospectus supplement will be filed with the SEC and will be available on their website [4] Group 3: Company Overview - Nektar Therapeutics is focused on developing treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (REZPEG) [6] - The company is evaluating several drug candidates in clinical trials, including NKTR-255, an investigational IL-15 receptor agonist [6]

Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The company's lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator currently in two Phase 2b clinical trials for atopic dermatitis and alopecia areata [3] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer, in several ongoing clinical trials [3] Upcoming Events - Nektar Therapeutics will participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, with a webcast available at 1:30 p.m. Eastern Time [1] - The fireside chat will be accessible via the webcast link and on the Investor Events section of the Nektar website, with a replay available for 30 days [1]